Prehospital topical hemostatic agents - A review of the current literature |
Prehospital topical hemostatic agents – A review of the current literature
PHTLS
Executive Committee
Lance
E. Stuke, M.D. MPH
Background:
The 7th edition PHTLS
textbook discusses the use of topical hemostatic agents which were are available
for prehospital use. Products come and go from the market so it is difficult to
remain current on all available products. Additionally, older products may
still be in use due to surplus, although they may not be commercially
available. Data on many of these
products is based primarily on military reports and very little data is
available on their use in the civilian prehospital setting. The vast majority
of these products have been researched and developed for use in the military
setting in Iraq and Afghanistan although some limited civilian data is also
available. At the time of printing of the 7th edition of PHTLS, only
Combat Gauze has been recommended by the Tactical Combat Casualty Care
Committee (COTCCC) for military use.
The
perfect hemostatic dressing does not exist. Ideally, the dressing should be
lightweight, easy to store, and able to be rapidly applied to a hemorrhaging
wound. It should be conformable to the wound, allowing the hemostatic agent to reach
areas of injury which are difficult to access with direct pressure (i.e. deep
groin wounds). The dressing should cause minimal local tissue destruction, be
easily removable from the wound, and not contain particles which can spread
systemically. Finally, the dressing must not be washed away by rapid bleeding
from high-flow blood vessels.
Manufacturers have tried various methods to
deliver hemostatic agents into bleeding wounds. Some products are packaged into
a granular form which can be poured directly into the wound. Others are
incorporated into a dressing or mesh which allows the provider to apply direct
pressure to the site of injury. This dressing can be formed either as a rigid
bandage, a small bag, or a gauze which must be unrolled prior to application.
Each method of preparation has distinct advantages and disadvantages depending
on the location and type of injury being treated.
Literature
and Product Review:
HemCon:
HemCon dressing (Hemorrhage Control Technologies, Portland, OR), is composed of
chitosan, a substance derived from arthropod skeletons. Chitosan dressings are
thought to function by mechanically sealing the wound and adhering to
surrounding tissue. HemCon is a dual-sided 4 x 4 inch rectangular bandage: a
chitosan-containing active side which must be placed directly on the wound and
a nonstick side which the provider uses to apply pressure. The efficacy of
HemCon depends entirely on the bandage adhering well to the wound, which is
difficult in wounds which aren’t flat and easily accessible. The bandage isn’t
flexible and can break when forced into a wound. It is best applied to flat,
superficial wounds which are easily accessible. HemCon has been studied in both
the military and civilian settings. The military demonstrated a 97% success
rate in controlling bleeding with HemCon.1,2 The civilian experience has been less
optimistic, controlling bleeding in 27 of 34 cases studied (79%). Of the seven
failures, six were felt to be due to user error, possibly due to less training by
civilian EMS providers in the proper use of the product.3 An
additional study using a complex groin injury model in swine noted an increase
in the rate of rebleeding and mortality between those treated with HemCon versus
QuikClot. The authors noted that
application of HemCon was more difficult than other agents and all failures of
HemCon were due to the bandage not adhering to the injured tissue to which it
was applied.4
As
previously noted, a disadvantage of the HemCon dressing is that it is
relatively non-conformable and difficult to pack into deeper wounds. ChitoFlex
is the latest development from HemCon Medical Technologies. It utilizes the
same chitosan-based hemostatic agent but packages it into a gauze form. This
allows the dressing to be packed into deep bleeding wounds for improved access
to the site of hemorrhage. ChitoFlex is available in several sizes, including
1”x3”, 3”x9”, and as a 3”x28” roll. In one study, ChitoFlex was found to be
equivalent, but not superior to QuikClot and Celox (a chitosan granule).5
WoundStat: WoundStat
was an FDA-approved mineral-based agent consisting of granular smectite, a
nonmetallic clay. When the granules were exposed to blood they absorbed water,
swelled, and formed a clay paste with strong adhesiveness to the surrounding
tissue. Initial studies were promising6,7,8 and it was used by the U.S. Army for a short
time. However, later data demonstrated that the granules could cause injury to
the blood vessels and make repair difficult. The granules were also shown to
enter the circulatory system and cause thrombosis in distal organs.9
Because of these potentially serious side effects, the U.S. Army announced in
April 2009 that WoundStat would no longer be used by their medical personnel.
QuikClot: QuikClot
(Z-Medica, Wallingford, CT) is a granular product consisting of kaolin, which
is a combination of inert minerals such as silicon, aluminum, magnesium, and
sodium found in volcanic rock. When placed in a bleeding wound, it absorbs
water thereby increasing the local concentration of clotting factors,
platelets, and red blood cells to stimulate clot formation. A byproduct of its
mechanism is a severe exothermic reaction, with heat generation of up to 70̊ C
(158o F). This heat generation causes local tissue destruction and
even burns. QuikClot has been studied in both the military and civilian sector,
with up to 92% effectiveness in stopping hemorrhage.10 QuikClot was
issued to U.S. soldiers in the Iraq and Afghanistan conflicts. Civilian use has
been by a wide range of providers, including EMT/firefighters, paramedics, and
police. Examples of civilian use include treatment of severe lacerations,
gunshot wounds to the neck and even hemodialysis catheter dislodgement. Trauma
surgeons have also used QuikClot for successful treatment of bleeding during
surgery in the chest, abdomen, and pelvis. QuikClot was noted to have two
significant weaknesses. Since it is a granular powder poured into a wound, it
had limited usefulness in high-pressure bleeding (i.e. femoral artery bleed) as
the granules were washed away by the bleeding before they were able to form a
clot. Furthermore, the heat generated from its use was associated with several burns.
QuikClot production
was stopped after development of several newer generation products. These newer
generation products have minimal heat production and are packaged both as
gauzes and in a bagged form. Currently Z-Medica sells QuikClot packaged in
2”x2” and 4”x4” gauze pads for use on superficial lacerations which don’t have
severe bleeding. QuikClot has also developed a small zeolite-impregnated pad
(QuikClot ACS+) and as a laparotomy pad (QuikClot Trauma Pad) for use by trauma
surgeons in the operating room for cases of severe bleeding during surgery.
This later product remains in the research phase and is not yet approved for
widespread use.
Combat GauzeTM
is a 3”x4 yard long roll of nonwoven gauze
impregnated with kaolin. Combat Gauze has all the advantages of normal gauze
(easy application, flexible, large coverage area, and easily removable) with
the additional advantage of hemostatic function from the kaolin. It is designed
for packing into deep wounds which are actively bleeding (i.e. arterial injury
in the groin). Prehospital personnel can also use combat gauze as they would
any standard Kerlix gauze. Combat Gauze was recently compared to several newer
generation products, including the HemCon RTS, and found to be superior and had
no apparent side effects.11 A study from the Israel Defense Force
reviewed fourteen uses of Combat Gauze and noted a 79% success rate.12
The authors noted that in the three instances where Combat Gauze was
unsuccessful, the soldiers had such severe injuries that only surgical control
was successful. One of the three soldiers died from the severity of his wounds.
Currently, Combat Gauze is the only product endorsed by the Tactical Combat
Casualty Care Committee and they recommend it as first line treatment for
life-threatening hemorrhage on external wounds not amendable to direct pressure
and tourniquet placement.
A disadvantage
of most topical hemostatic agents is they require 2-5 minutes of direct
pressure to be effective. This amount of time is often not available during
care under fire situations seen in combat or during a mass casualty situation.
A study published in the Journal of Trauma compared Combat Gauze (used by the
U.S. military), Celox Gauze (used by the United Kingdom), and standard Kerlix
gauze.13 A 6mm side-wall injury was created in swine, 30 seconds of
free hemorrhage was allowed, and wounds were packed with one of the three
gauzes. The animals were resuscitated with Lactated Ringers to maintain
baseline mean arterial pressure. The authors noted no difference in success of
either dressing. The Kerlix gauze was packed faster than Combat and Celox
Gauze. There was no difference in survival, dressing success, or blood loss
between the three dressings. The authors note they were somewhat surprised by
this finding and note that in care under fire situations where tourniquet use
is not an option, standard gauze packed in a wound performed equally well to
Combat Gauze and Celox Gauze.
A study from the
Naval Medical Center in Portsmouth, VA compared several commercially available
topical hemostatic agents to the application of direct pressure with standard
gauze.14 The authors used a swine model with a severed femoral
artery and vein to simulate a high-velocity projectile injury with jagged
surrounding muscle. Combat Gauze, WoundStat, Celox-A, and ChitoFlex were
applied to the created injuries per the manufacturer recommendations. They were
then compared to each other and to standard gauze applied using direct
pressure. Manual pressure was held for 5 minutes and any bleeding occurring
after this was considered a failure of hemostasis. Primary outcome measures
were failure of initial hemostasis and the incidence of rebleeding. Secondary
measures included total blood loss, amount of rebleeding, and survival.
WoundStat performed more poorly than Celox-A in achieving initial hemostasis
and in the incidence of rebleeding. Surprising to the authors, standard gauze
and direct pressure performed equally as well as the 4 commercially available
topical hemostatic agents. There were no significant differences in failure of
initial hemostasis, rebleeding, or death between standard gauze and the other
agents.
Summary:
- Numerous
topical hemostatic products have been developed and released onto the market.
- Some of these
products have since been discontinued, while others are widely used.
-Economic and
medical considerations continue to make this a rapidly evolving and growing area of prehospital care. It is
important for the EMS provider to remain cognizant
of these products and their advantages, disadvantages, and complications as they continue to evolve.
- Recent data
suggests direct pressure with standard gauze may be equally effective as commercially available hemostatic agents.
Providers should consider this when attempting
to control hemorrhage. Principles of adequate direct pressure and wound packing continue to be the
cornerstone of controlling severe traumatic bleeding from penetrating extremity wounds.
PHTLS
Recommendation: Topical
hemostatic agents may be used to control hemorrhage occurring in sites not
amenable to tourniquet placement and which cannot be controlled by direct
pressure alone.
Bibliography
1. Achneck
HE, Sileshi B, Jamiolkowski RM, et al. A comprehensive review of topical
hemostatic agents: Efficacy and recommendations for use. Annals of Surgery 2010; 251: 217-228.
2. Mabry
R and McManus JG. Prehospital advances in the management of severe penetrating
trauma. Crit Care Med. 2008:36(7);S258-266.
3. Brown
MA, Daya MR, Worley JA. Experience with chitosan dressings in a civilian EMS
system. J Emerg Med. 2009;62:239-243.
4. Kozen
BG, Kircher SJ, Henao J, et al. An alternative hemostatic dressing: comparison
of CELOX, HemCon, and QuikClot.Acad Emerg
Med. 2008; 15:74-81.
5. Devlin
JJ, Kircher S, Kozen BG, et al. Comparison of ChitoFlex, CELOX, and QuikClot in
control of hemorrhage. J Emerg Med.
2009 Apr 1 (Epub ahead of print).
6. Ward
KR, Tiba MH, Holbert WH, et al. Comparison of a new hemostatic agent to current
combat hemostatic agents in a swine model of lethal arterial hemorrhage. J Trauma. 2007;63:276-284.
7. Kheirabadi
BS, Edens JW, Terrazas IB, et al. Comparison of new hemostatic granules/powders
with currently deployed hemostatic products in a lethal model of extremioty
arterial hemorrhage in swine. J Trauma. 2009;66:316-328.
8. Arnaud
F, Parreno-Sadalan D, Tomori T, et al. Comparison of 10 hemostatic dressings in
a groin transaction model in swine. J
Trauma. 2009;67:848-855.
9. Bheirabadi
BS, Mace JE, Terrazas IB, et al. Safety evaluation of new hemostatic agents,
smectite granules, and kaolin-coated gauze in a vascular injury wound model in
swine. J Trauma. 2010;68:269-278.
10. Rhee
P, Brown C, Martin M, et al. QuikClot use in trauma for hemorrhage control:
case series of 103 documented uses. J
Trauma. 2008;64:1093-1099.
11. Kheirabadi
BS, Scherer MR, Estep JS, et al. Determination of efficacy of new hemostatic
dressings in a model of extremity arterial hemorrhage in swine. J Trauma. 2009;67:450-460.
12. Ran
Y, Hadad E, Daher S, et al. QuikClot Combat Gauze Use for Hemorrhage Control in
Military Trauma: January 2009 Israel Defense Force Experience in the Gaza Strip
– A Preliminary Report of 14 Cases. Prehop
Disaster Med 2010;25(6):584-588.
13. Watters
JM, Van PY, Hamilton GJ, et al. Advanced Hemostatic Dressings Are Not Superior
to Gauze for Care Under Fire Scenarios. J
Trauma. 2011;70:1413-1419.
14. Littlejohn
LF, Devlin JJ, Kircher SS, et al. Comparison of Celox-A, ChitoFlex, WoundStat,
and Combat Gauze Hemostatic Agents Versus Standard Gauze Dressing in Control of
Hemorrhage in a Swine Model of Penetrating Trauma. Acad Emerg Med. 2011:18(4);340-350.